TCRS Thank You - Alloy Therapeutics

Thank you for reaching out to Alloy Tx

Join our Webinar Tuesday February 14th at 11:30am ET
Or register to receive the recording if you can’t make it live

TCR mimics (TCRm) and engineered TCRs enable drug developers to work against the vast space of intracellular proteins (>70% of the human proteome) that have not been addressed by conventional cancer immunotherapies. Despite tremendous potential therapeutic values, the discovery of highly specific TCRm and TCR-based therapeutics remains a challenge for many due to inaccessibility to the required foundational technologies. Alloy’s Keyway TCR Discovery group provides comprehensive proprietary technology and capabilities for the end-to-end discovery of these modalities. In this webinar, leading scientists at the helm of Keyway TCRm Discovery campaigns will present:

1. An overview of common challenges to intracellular protein-targeting drug discovery

2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities

3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target

Join us for an informative discussion, and be sure to bring your questions.

Name(Required)

First Last

Email(Required)

Organization

Job Title

Where are you in your current TCRm discovery efforts?

Do you have any specific questions for the speakers about TCRm discovery?

Our team has received your request and we will follow up with you shortly.

Review our recent Case Studies

ATX-Gx(TM) Biotech Licensee Discovering Novel Therapeutics

ATX-Gx™ Biotech Licensee Discovering Novel Therapeutics

Partnering with Target-Rich Biotech Companies

Democratizing Access for Academic Entrepreneurs

Targeting GPCRs with Alloy Antibody Discovery Services

Access the white paper

Thanks for your interest in our white paper, Targeting GPCRs with DeepImmune Antibody Discovery.

G protein-coupled receptors (GPCRs) play a central role in multiple physiological functions, from endocrine sensing to neurotransmission to chemotaxis of immune cells. This class has long been an attractive target for novel antibody drug discovery campaigns in multiple disease indications, but their unique nature produces many challenges for in vivo antibody discovery. In this white paper, we detail how our humanized mouse discovery platform, the ATX-Gx™, have been successfully utilized for GPCR-targeted antibody discovery, Alloy Antibody Discovery’s DeepImmune™ module builds on this robust in vivo discovery platform, coupling best-in-class immunogen production with multiple binder recovery approaches, and advanced machine-learning-based techniques for lead identification and optimization.

Keyway TCR Mimic Discovery Webinar

Access the webinar recording

I’d like more material about Keyway TCR Discovery

Thanks for your interest in our recent Keyway TCRm Discovery webinar, Increasing Target Specificity and Tackling Intracellular Targets for TCRm Therapeutics Development with Keyway’s TCRm Discovery Offering. In it, the team at the helm of our TCR mimic discovery campaigns shared:

1. An overview of common challenges to intracellular protein-targeting drug discovery
2. Keyway’s industry-leading solutions to TCRm/TCR-based therapeutic discovery including its proprietary specificity screening and high-quality pMHC complex antigen production capabilities
3. A case study featuring the discovery of a panel of highly specific, functional TCRm binders against an intracellular immuno-oncology target

Upon filling out this form, you will receive an email with a link to the webinar recording.